Heron Therapeutics, Inc. /De/ financial data

Symbol
HRTX on Nasdaq
Location
4242 Campus Point Court, Suite 200, San Diego, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 4, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 163 % -31.2%
Quick Ratio 47.9 % -11.3%
Debt-to-equity -1.38K % -95.5%
Return On Equity 72.9 % -5.03%
Return On Assets -5.72 % +55%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 183M shares +20.6%
Common Stock, Shares, Outstanding 152M shares +1.23%
Entity Public Float 394M USD +230%
Common Stock, Value, Issued 1.83M USD +20.8%
Weighted Average Number of Shares Outstanding, Basic 170M shares +11.5%
Weighted Average Number of Shares Outstanding, Diluted 170M shares +11.5%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 11.9M USD -44.3%
Selling and Marketing Expense 47.9M USD -0.97%
General and Administrative Expense 53.3M USD -4.3%
Costs and Expenses 113M USD -9.82%
Operating Income (Loss) 1.6M USD +8.19%
Net Income (Loss) Attributable to Parent -13.6M USD +51.5%
Earnings Per Share, Basic 0 USD/shares +33.3%
Earnings Per Share, Diluted 0 USD/shares +25%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 43.1M USD +67.3%
Cash, Cash Equivalents, and Short-term Investments 55.5M USD -21.7%
Accounts Receivable, after Allowance for Credit Loss, Current 81M USD +20.9%
Inventory, Net 70M USD +52.4%
Assets, Current 229M USD +17.5%
Property, Plant and Equipment, Net 13M USD -15.9%
Operating Lease, Right-of-Use Asset 708K USD -79.6%
Other Assets, Noncurrent 5.88M USD -12.3%
Assets 249M USD +12.8%
Accounts Payable, Current 12M USD +18%
Employee-related Liabilities, Current 8.75M USD +2.54%
Liabilities, Current 89.7M USD +4.87%
Operating Lease, Liability, Noncurrent 522K USD -85.2%
Other Liabilities, Noncurrent 4.69M USD +1848%
Liabilities 234M USD -10.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax 0 USD -100%
Retained Earnings (Accumulated Deficit) -1.94B USD -0.71%
Stockholders' Equity Attributable to Parent 14.9M USD
Liabilities and Equity 249M USD +12.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -8.87M USD +6.79%
Net Cash Provided by (Used in) Financing Activities 64K USD
Net Cash Provided by (Used in) Investing Activities 2.27M USD +77.9%
Common Stock, Shares Authorized 400M shares +77.8%
Common Stock, Shares, Issued 152M shares +1.23%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -6.53M USD +20.6%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 43.1M USD +67.3%
Interest Paid, Excluding Capitalized Interest, Operating Activities 636K USD -2%
Deferred Tax Assets, Valuation Allowance 419M USD -2.48%
Deferred Tax Assets, Gross 420M USD -2.63%
Operating Lease, Liability 780K USD -79.3%
Payments to Acquire Property, Plant, and Equipment 109K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -13.6M USD +51.2%
Lessee, Operating Lease, Liability, to be Paid 3.14M USD -50.1%
Property, Plant and Equipment, Gross 32.7M USD -12.1%
Operating Lease, Liability, Current 780K USD -76%
Lessee, Operating Lease, Liability, to be Paid, Year Two 3.14M USD +3.56%
Lessee, Operating Lease, Liability, to be Paid, Year One 3.14M USD -0.48%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 5K USD -96.9%
Deferred Tax Assets, Operating Loss Carryforwards 324M USD +0.99%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 2.5M shares 0%
Unrecognized Tax Benefits 10.9M USD 0%
Additional Paid in Capital 1.94B USD +3.21%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 551K USD -20%
Share-based Payment Arrangement, Expense 10.5M USD -30.3%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%